Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 11,204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Urogenital Diseases Clear all
Terminated Phase 1 Interventional

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine, Anakinra
Biological · Drug
Lead sponsor
Tceleron Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Kansas City, Kansas • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

NCT00737893
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
Placebo, Erythropoietin (EPO)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 19, 2026, 10:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

A Study of CDX-585 in Patients With Advanced Malignancies

NCT05788484
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions
CDX-585
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 19, 2026, 10:32 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

NCT07781852
View directory record Official record
Conditions
Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions
[64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
Drug · Device · Procedure
Lead sponsor
Lumina Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Prostate Cancer

NCT00039299
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Study of Intermittent OSI-906 Dosing

NCT00514306
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 19, 2026, 10:32 AM EDT
Recruiting Phase 3 Interventional

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

NCT07548164
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife System, Stereotactic Body Radiation Therapy
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 19, 2026, 10:32 AM EDT
Completed No phase listed Observational

The Drug Induced Renal Injury Consortium

NCT02159209
View directory record Official record
Conditions
Acute Kidney Injury, Adverse Drug Reaction, Acute Kidney Failure, Kidney Failure, Kidney Disease
Interventions
Not listed
Lead sponsor
Ravindra Mehta
Other
Eligibility
2 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

NCT04818216
View directory record Official record
Conditions
SARS-CoV-2 Infection, Acute Kidney Injury
Interventions
Placebo, Nicotinamide riboside
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York • San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

NCT00061347
View directory record Official record
Conditions
Prostate Cancer, Cancer
Interventions
Fiducial marker placement
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Not applicable Interventional

Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads

NCT01054534
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Placement of interstim lead
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

NCT00216099
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pemetrexed, Folic Acid, Vitamin B12
Drug · Dietary Supplement
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
Galesburg, Illinois • Elkhart, Indiana • Fort Wayne, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

NCT03102021
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
erythropoietin, saline
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

NCT04534114
View directory record Official record
Conditions
End Stage Renal Disease Requiring Hemodialysis
Interventions
Fesomersen sodium (BAY2976217), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 19, 2026, 10:32 AM EDT
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Not applicable Interventional

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conservative dialysis strategy, TIW dialysis strategy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 19, 2026, 10:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 19, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

NCT02386826
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
Interventions
INC280, bevacizumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 19, 2026, 10:32 AM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 10:32 AM EDT
Completed No phase listed Observational

A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

NCT05858749
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 19, 2026, 10:32 AM EDT